Skip to main content

Table 1 Comparison of survivors and non-survivors after ECMO

From: Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study

 

Non-survivors (n = 117)

Survival to discharge (n = 187)

P-value

Baseline clinical characteristics

   

Age (years)

54 (50 to 57)

46 (43 to 48)

<0.001

Immunocompromised statea

37 (31.6%)

26 (13.9%)

<0.001

Sequential organ failure assessment score

13 (12 to 14)

11 (11 to 12)

0.001

Continuous veno-venous hemofiltration pre-ECMO

45 (38.5%)

36 (19.3%)

<0.001

Classification of acute lung injuryb

  

0.022

- Group 1: Pulmonary

56 (47.9%)

107 (57.2%)

 

- Group 2: Extra-pulmonary

36 (30.8%)

36 (19.3%)

 

- Group 3: Trauma

10 (8.6%)

29 (15.5%)

 

- Group 4: Others

15 (12.8%)

15 (8.0%)

 

Pre-ECMO duration (days) of

   

- Hospitalization

10 (8 to 12)

5 (4 to 7)

0.023

- Mechanical ventilation

5 (3 to 7)

2 (2 to 3)

0.013

Baseline cardiorespiratory parameters

Minute ventilation (L/minute)

11.2 (10.6 to 12.0)

10.4 (10.0 to 10.9)

0.038

Baseline laboratory parameters

Lactate (mmol/L)

38 (30 to 47)

23 (20 to 27)

0.002

Lactate dehydrogenase (U/L)

510 (446 to 608)

452 (408 to 499)

0.076

Bilirubin (mg/dL)

1.2 (0.9 to 1.6)

0.9 (0.8 to 1.1)

0.060

ASAT (U/L)

122 (96 to 159)

78 (65 to 96)

0.005

Hemoglobin (g/dL)

9.8 (9.4 to 10.3)

10.9 (10.5 to 11.3)

<0.001

D-dimer (mg/L)

11 (9 to 14)

8 (7 to 10)

0.022

Procedural characteristics of ECMO treatment

Transport-ECMO (no/yes)

34 (29.1%)

99 (52.9%)

<0.001

Red cell transfusions (about 320 mL) per patient

8 (6 to 9)

3 (3 to 4)

<0.001

Plasma transfusions (about 250 mL) per patient

3 (2 to 5)

0 (0 to 1)

0.001

Platelet transfusions (about 270 mL) per patient

1 (0 to 1)

0 (0 to 0)

<0.001

Laboratory and cardiorespiratory status after one day on ECMO

Minute ventilation (L/minute)

5 (5 to 6)

4 (4 to 5)

0.011

Tidal volume (mL)

305 (278 to 332)

278 (262 to 294)

0.097

Norepinephrine infusion (μg/minute/kg)

0.18 (0.13 to 0.25)

0.12 (0.09 to 0.14)

0.041

Blood gas analysis

   

- FiO2 (%)

65 (60 to 68)

55 (52 to 58)

<0.001

- PaO2/FiO2 (mmHg)

122 (112 to 133)

146 (137 to 155)

<0.001

Laboratory parameters

   

- Lactate (mmol/L)

36 (27 to 47)

24 (21 to 28)

0.002

- C-reactive protein (mg/L)

162 (143 to 180)

214 (196 to 231)

<0.001

- Bilirubin (mg/dL)

1.9 (1.5 to 2.3)

1.1 (1.0 to 1.3)

0.015

- Lactate dehydrogenase (U/L)

584 (502 to 717)

511 (462 to 573)

0.054

- International normalized ratio

1.38 (1.32 to 1.48)

1.27 (1.24 to 1.31)

0.002

  1. Continuous variables are shown as median (95% confidence interval), categorical variables as n (%). Differences for survivors and non-survivors are shown for P <0.1. A wider comparison can be seen in Additional file 4. aImmunocompromised state included hematological malignancies, solid tumors, solid organ transplantation, high-dose or long-term corticosteroid or other immunosuppressive therapy, or human immunodeficiency virus infection. bGroup 1: primary lung failure, including bacterial, viral, fungal or aspiration pneumonia; Group 2: extra-pulmonary sepsis with secondary lung injury; Group 3: multiple trauma with ARDS; Group 4: other pathologies, including near drowning, chronic lung diseases, such as lung fibrosis and lung transplantation. ASAT, aspartate aminotransferase; ECMO, extracorporeal membrane oxygenation; FiO2,fraction of inspired oxygen; PaO2/FiO2, ratio of partial arterial oxygen pressure/fraction of inspired oxygen; SOFA, Sequential Organ Failure Assessment.
Back to article page

Critical Care

ISSN: 1364-8535